<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04565678</url>
  </required_header>
  <id_info>
    <org_study_id>AG348-C-019</org_study_id>
    <nct_id>NCT04565678</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Relative Bioavailability and Effect of Food on the Coated Granule Formulation of Mitapivat in Healthy Participants</brief_title>
  <official_title>A Phase 1, Open-label, Randomized 4-period Crossover Study to Assess the Relative Bioavailability and Effect of Food on the Coated Granule Formulation of Mitapivat in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Agios Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Agios Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess the relative bioavailability of the mitapivat&#xD;
      coated granule formulation compared to the tablet formulation following a single oral dose of&#xD;
      mitapivat under fasted conditions in healthy adult participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 21, 2020</start_date>
  <completion_date type="Actual">December 3, 2020</completion_date>
  <primary_completion_date type="Actual">December 3, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of Mitapivat Under Fasted Conditions</measure>
    <time_frame>Pre-dose and multiple time points post-dose (up to 72 hours)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration (AUC0-t) of Mitapivat Under Fasted Conditions</measure>
    <time_frame>Pre-dose and multiple time points post-dose (up to 72 hours)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity (AUC0-∞) of Mitapivat Under Fasted Conditions</measure>
    <time_frame>Pre-dose and multiple time points post-dose (up to 72 hours)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Concentration (Tmax) of Mitapivat Under Fasted Conditions</measure>
    <time_frame>Pre-dose and multiple time points post-dose (up to 72 hours)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of Mitapivat Under Fed Conditions</measure>
    <time_frame>Pre-dose and multiple time points post-dose (up to 72 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t of Mitapivat Under Fed Conditions</measure>
    <time_frame>Pre-dose and multiple time points post-dose (up to 72 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞ of Mitapivat Under Fed Conditions</measure>
    <time_frame>Pre-dose and multiple time points post-dose (up to 72 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Mitapivat Under Fed Conditions</measure>
    <time_frame>Pre-dose and multiple time points post-dose (up to 72 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Bioavailability (Frel) Under Fasted and Fed Conditions</measure>
    <time_frame>Pre-dose and multiple time points post-dose (up to 72 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve from Time Zero to Twelve Hours (AUC0-12) of Mitapivat Under Fasted and Fed Conditions</measure>
    <time_frame>Pre-dose and multiple time points post-dose (up to 72 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Plasma Terminal Elimination Half-life (t½) of Mitapivat Under Fasted and Fed Conditions</measure>
    <time_frame>Pre-dose and multiple time points post-dose (up to 72 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Plasma Clearance (CL/F) of Mitapivat Under Fasted and Fed Conditions</measure>
    <time_frame>Pre-dose and multiple time points post-dose (up to 72 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) of Mitapivat Under Fasted and Fed Conditions</measure>
    <time_frame>Pre-dose and multiple time points post-dose (up to 72 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Elimination Rate Constant (λz) of Mitapivat Under Fasted and Fed Conditions</measure>
    <time_frame>Pre-dose and multiple time points post-dose (up to 72 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Event (AEs)</measure>
    <time_frame>Up to approximately 9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With AEs, Graded by Severity</measure>
    <time_frame>Up to approximately 9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Abnormal Clinical Laboratory Values</measure>
    <time_frame>Up to approximately 9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Abnormal Findings for 12-lead Electrocardiogram (ECG) Parameters</measure>
    <time_frame>Up to approximately 9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Abnormal Findings for Vital Signs Parameters</measure>
    <time_frame>Up to approximately 9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Abnormal Physical Examination Findings</measure>
    <time_frame>Up to approximately 9 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Treatment Sequence 1: ABCD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 1) followed by Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 2) followed by Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 3) followed by Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 2: BDAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 1) followed by Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 2) followed by Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 3) followed by Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 3: CADB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 1) followed by Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 2) followed by Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 3) followed by Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 4: DCBA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 1) followed by Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 2) followed by Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 3) followed by Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitapivat tablets</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>Treatment Sequence 1: ABCD</arm_group_label>
    <arm_group_label>Treatment Sequence 2: BDAC</arm_group_label>
    <arm_group_label>Treatment Sequence 3: CADB</arm_group_label>
    <arm_group_label>Treatment Sequence 4: DCBA</arm_group_label>
    <other_name>AG-348</other_name>
    <other_name>AG-348 sulfate hydrate</other_name>
    <other_name>Mitapivat sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitapivat coated granules</intervention_name>
    <description>Oral coated granules</description>
    <arm_group_label>Treatment Sequence 1: ABCD</arm_group_label>
    <arm_group_label>Treatment Sequence 2: BDAC</arm_group_label>
    <arm_group_label>Treatment Sequence 3: CADB</arm_group_label>
    <arm_group_label>Treatment Sequence 4: DCBA</arm_group_label>
    <other_name>AG-348</other_name>
    <other_name>AG-348 sulfate hydrate</other_name>
    <other_name>Mitapivat sulfate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index between 18.0 and 32.0 kilograms per square meter (kg/m^2), inclusive;&#xD;
&#xD;
          -  In good health, determined by no clinically significant findings from medical history,&#xD;
             physical examination, 12-lead electrocardiogram (ECG), vital signs measurements, and&#xD;
             clinical laboratory evaluations;&#xD;
&#xD;
          -  Females will not be pregnant or lactating, and females of childbearing potential and&#xD;
             males will agree to use contraception;&#xD;
&#xD;
          -  Participant has no clinically significant history or presence of ECG findings as&#xD;
             judged by the Investigator at Screening and Check-in.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant history or clinical manifestation of any metabolic, allergic,&#xD;
             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,&#xD;
             gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as&#xD;
             determined by the Investigator;&#xD;
&#xD;
          -  History of significant hypersensitivity, intolerance, or allergy to any drug compound,&#xD;
             food, including the 2 soft foods administered in this study, or other substance,&#xD;
             unless approved by the Investigator;&#xD;
&#xD;
          -  History of stomach or intestinal surgery or resection including cholecystectomy that&#xD;
             would potentially alter absorption and/or excretion of orally administered drugs&#xD;
             (uncomplicated appendectomy and hernia repair will be allowed);&#xD;
&#xD;
          -  History of any malignancy with the exception of non-melanomatous skin cancer in situ,&#xD;
             cervical carcinoma in situ, or breast carcinoma in situ;&#xD;
&#xD;
          -  Participant has liver function tests including alanine transaminase (ALT), aspartate&#xD;
             transaminase (AST), alkaline phosphatase, and total bilirubin that are greater than&#xD;
             the upper limit of normal at Screening or Check-in;&#xD;
&#xD;
          -  Participant has platelet count or hemoglobin and hematocrit values that are below the&#xD;
             lower limit of normal at Screening or Check-in;&#xD;
&#xD;
          -  Confirmed (eg, original value and 2 consecutive repeat measurements) systolic blood&#xD;
             pressure &gt;150 or &lt;90 millimeters of mercury (mmHg), diastolic blood pressure &gt;90 or&#xD;
             &lt;50 mmHg, and pulse rate &gt;100 or &lt;45 beats per minute (bpm);&#xD;
&#xD;
          -  Confirmed QT interval corrected for heart rate using Fridericia's method (QTcF) &gt;450&#xD;
             milliseconds (msec) (male participants) or &gt;470 msec (female participants);&#xD;
&#xD;
          -  History of active alcoholism or drug/chemical abuse within 2 years prior to Check-in;&#xD;
&#xD;
          -  Alcohol consumption of &gt;21 units per week for males and &gt;14 units for females;&#xD;
&#xD;
          -  Positive urine drug screen at Screening or positive alcohol breath test result or&#xD;
             positive urine drug screen at Check-in;&#xD;
&#xD;
          -  Positive hepatitis panel and/or positive human immunodeficiency virus test;&#xD;
&#xD;
          -  Participants with an active infection requiring systemic antimicrobial therapy, or&#xD;
             with an active infection deemed clinically significant by the Investigator during&#xD;
             Screening;&#xD;
&#xD;
          -  Participation in a clinical study involving administration of an investigational drug&#xD;
             (new chemical entity) in the past 30 days or 5 half-lives prior to dosing (whichever&#xD;
             is longer);&#xD;
&#xD;
          -  Participant has used any over-the-counter medications, including herbal or nutritional&#xD;
             supplements, within 28 days (or 5 half-lives, whichever is longer) before the first&#xD;
             dose of study drug until after the Follow up phone call;&#xD;
&#xD;
          -  Participant has used any prescription (excluding hormone replacement therapy and&#xD;
             hormonal birth control) medications within 30 days (or 5 half-lives, whichever is&#xD;
             longer) before the first dose of study drug until after the Follow up phone call;&#xD;
&#xD;
          -  Use of tobacco- or nicotine-containing products including cigarettes, snuff, nicotine&#xD;
             patch, nicotine chewing gum, vaporizers, or inhalers, within 6 months prior to&#xD;
             Screening until after the Follow up phone call, or positive cotinine at Screening or&#xD;
             Check-in;&#xD;
&#xD;
          -  Participant must refrain from marijuana or cannabinol-containing products for 7 days&#xD;
             before Screening until after the Follow up phone call;&#xD;
&#xD;
          -  Ingestion of poppy seed within 7 days prior to Check-in until after the Follow up&#xD;
             phone call;&#xD;
&#xD;
          -  Participant has consumed grapefruit or grapefruit juice, Seville orange, or Seville&#xD;
             orange containing products (eg, marmalade) within 7 days before the first dose of&#xD;
             study drug until after the Follow up phone call;&#xD;
&#xD;
          -  Participant has consumed caffeine- or xanthine-containing products within 24 hours&#xD;
             prior to first dose of study drug until after the Follow up phone call;&#xD;
&#xD;
          -  Participant has consumed vegetables from the mustard green family (eg, kale, broccoli,&#xD;
             watercress, collard greens, kohlrabi, Brussels sprouts, and mustard), or charbroiled&#xD;
             meats for 7 days prior to first dose of study drug until after the Follow-up phone&#xD;
             call;&#xD;
&#xD;
          -  Participant is involved in strenuous activity or contact sports from 7 days before&#xD;
             Check-in until after the Follow-up phone call;&#xD;
&#xD;
          -  Receipt of blood products within 2 months prior to Check-in;&#xD;
&#xD;
          -  Participant has donated blood or blood products &gt;450 milliliters (mL) within 30 days&#xD;
             before the first dose of study drug;&#xD;
&#xD;
          -  Participant has a poor peripheral venous access;&#xD;
&#xD;
          -  Have previously completed or withdrawn from this study or any other study&#xD;
             investigating mitapivat sulfate, and have previously received the mitapivat sulfate;&#xD;
&#xD;
          -  Participant has a history of allergy to sulfonamides (eg, co-trimoxazole antibiotic,&#xD;
             silver sulfadiazine topical antibiotic for burn wounds) that has been characterized by&#xD;
             acute hemolytic anemia, drug-induced liver injury, anaphylaxis, rash of erythema&#xD;
             multiforme type, or Stevens-Johnson syndrome.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Covance Clinical Research Unit Inc.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 22, 2020</study_first_submitted>
  <study_first_submitted_qc>September 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2020</study_first_posted>
  <last_update_submitted>December 9, 2020</last_update_submitted>
  <last_update_submitted_qc>December 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

